# Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

> **NCT06100705** · PHASE2 · RECRUITING · sponsor: **Yale University** · enrollment: 26 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Testosterone Cypionate
- **DRUG:** Sipuleucel-T

## Key facts

- **NCT ID:** NCT06100705
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-20
- **Primary completion:** 2027-12
- **Final completion:** 2028-03
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2025-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06100705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06100705, "Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06100705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*